MedTrace Logo

Identification of Risk Factors Parkinson's Disease by Convergence Strategy

NCT03536104 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2220

Last updated 2025-12-03

No results posted yet for this study

Summary

Using this convergence approach from a limited group of subjects with non-diseased controls, patients with Parkinson's disease or related diseases, we will be able to limit the number of potential genes of specific susceptibility to Parkinson disease. These genes will then be studied using a case-control genetic epidemiology approach. The risk of developing the disease will then be evaluated according to clinical, biological and environmental variables collected in Parkinson's subjects and healthy controls in the second group of subjects. The specificity of the genetic associations found will be evaluated in subjects with Parkinson's disease.

Conditions

  • Parkinson Disease

Sponsors & Collaborators

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • Alain DESTEE, MD, PhD · University Hospital, Lille

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-03-25
Primary Completion
2024-11-19
Completion
2024-11-19

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03536104 on ClinicalTrials.gov